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FAM49B, a novel regulator of mitochondrial function and
integrity that suppresses tumor metastasis
MS Chattaragada1,2, C Riganti3, M Sassoe4, M Principe1,2, MM Santamorena1,2, C Roux1,2, C Curcio1,2, A Evangelista5, P Allavena6,
R Salvia7, B Rusev8, A Scarpa8, P Cappello1,2,9 and F Novelli1,2,9
Mitochondrial dysregulation plays a central role in cancers and drives reactive oxygen species (ROS)-dependent tumor progression.
We investigated the pro-tumoral roles of mitochondrial dynamics and altered intracellular ROS levels in pancreatic ductal
adenocarcinoma (PDAC). We identified ‘family with sequence similarity 49 member B’ (FAM49B) as a mitochondria-localized protein
that regulates mitochondrial fission and cancer progression. Silencing FAM49B in PDAC cells resulted in increased fission and
mitochondrial ROS generation, which enhanced PDAC cell proliferation and invasion. Notably, FAM49B expression levels in PDAC
cells were downregulated by the tumor microenvironment. Overall, the results of this study show that FAM49B acts as a suppressor
of cancer cell proliferation and invasion in PDAC by regulating tumor mitochondrial redox reactions and metabolism.
Oncogene (2018) 37, 697–709; doi:10.1038/onc.2017.358; published online 23 October 2017
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC), whose 5-year survival
rate is as low as 6%,1,2 is one of the most aggressive malignancies,
because the disease is often diagnosed at a late stage, and its
treatment options are limited. PDAC has a very poor prognosis.3–5
Therefore, a better understanding of the mechanisms driving the
progression of this cancer is needed. Approximately 90% of all
PDACs acquire KRAS mutations,6 and the progression of these
tumors is also accompanied by an increase in cellular oxidative
stress levels.7–9
Mitochondria are the main source of reactive oxygen species
(ROS), and their functional state is modified during tumor
progression.10–13 Mitochondrial ROS play an essential role in cell
proliferation and tumorigenesis in PDAC.14,15 In particular,
mitochondrial fragmentation, a phenomenon known as ‘fission’,
is associated with increased energy demands and increased ROS
production.16,17 Mitochondrial fission is also associated with the
generation of new organelles. Fission is mainly regulated by
dynamin-related protein 1 (DRP1). DRP1 recruitment around
mitochondria results in the formation of spirals, which draw
together both the inner and the outer mitochondrial membranes
to allow mitochondrial division.18 Conversely, ‘fusion’, which is
required to reduce stress, is regulated by mitofusins 1 and 2
(MFN1/2), which fuse the outer membrane, and optic atrophy 1,
(OPA1), which fuses the inner membrane, creates elongated
mitochondria.19–21 Metabolic changes in cells lead to the
regulation of fission and fusion.22–24
Family with sequence similarity 49 member B (FAM49B) is
encoded by a highly conserved gene in mammals. In humans, the
FAM49B gene is localized on chromosome 8q24, encodes for a 37-
kDa protein composed of 324 amino-acid residues,25 and contains
a characteristic DUF1394 domain. Another FAM49B isoform of
~ 20 kDa lacks the first 123 amino acids due to alternative splicing
of its transcript. None of the isoforms contain any other known
functional motifs. To date, no functional data regarding this
protein have been published, and its role in cancer is unknown.
In this study, we investigated the expression and role of
FAM49B in PDAC. We demonstrated that FAM49B is highly
expressed in PDAC cell lines and that this expression is
downregulated in vivo by the surrounding tumor environment.
In PDAC cells, FAM49B is predominantly localized in the
mitochondria, and FAM49B gene knockdown leads to oxidative
stress that enhances tumor proliferation and invasiveness. Thus,
we have identified a novel ‘tumor suppressor’ gene that links the
inflammatory environment to mitochondrial dynamics.
RESULTS
FAM49B expression in PDAC
FAM49B expression levels in PDAC biopsy tissue samples (n= 93)
were analyzed by immunohistochemistry (Figure 1a). Most of the
PDAC biopsies (71%) displayed negative staining for FAM49B
(Figure 1a). However, the remaining biopsies (29%) displayed
positive staining for FAM49B (Figure 1a). We subsequently
evaluated the association between FAM49B expression and PDAC
patient clinical and pathological characteristics (Supplementary
Table 1). There were no significant differences in FAM49B
expression levels among patients of different ages or survival
times (Supplementary Figure 1A). However, there was a significant
difference in the rate of tumor lymph node (LN) invasion between
patients with positive and negative FAM49B expression. Specifi-
cally, the rate of LN invasion was much higher in patients who
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displayed negative FAM49B expression (P= 0.004) than in patients
who displayed positive FAM49B expression (Figures 1b and c).
A similar pattern of low FAM49B expression was observed in the
genetically engineered mouse (GEM) strains that spontaneously
develop PDAC (LSL-KrasG12D/+, Pdx-1-Cre (KC), LSL-KrasG12D/+,
LSL-Tp53R172H/+ and Pdx-1-Cre (KPC))26 (Figure 1d). To deter-
mine whether FAM49B expression is downregulated during
disease progression we examined KC and KPC mouse tissues
collected at different time points, namely 3, 6, 9 and 12 months of
age (n= 8/age). FAM49B expression was low in normal pancreatic
ducts (Figure 1d, left panels) and strongly expressed in most of the
ADM/ early pancreatic intraepithelial neoplasia (PanIN) lesions
(Figure 1d, mid panels), which represents early stages of the
disease. By contrast FAM49B staining was very faint in well-
established PDAC (Figure 1d, right panels). These results suggest
FAM49B expression is lost during the progression from early PanIN
to adenocarcinoma and the loss of correlates with its invasiveness.
FAM49B expression is downregulated by the tumor
microenvironment
Microarray analysis of FAM49B mRNA expression showed that
FAM49B was expressed at similarly low levels in normal pancreatic
duct samples and PDAC biopsy samples from both patients and
xeno-transplanted immunosuppressed (xeno-PDAC) mice. In
contrast, FAM49B was highly expressed in the Paca44 PDAC cell
line (Figure 2a). Additional mRNA analysis showed that FAM49B
expression levels were two- to threefold higher in six human PDAC
cell lines (BXPC3, T3M4, PT45, Mia-PA-CA2, CFPAC1 and Hs766T)
and elevated to a lesser extent in another two cell lines (L3.6pl and
Figure 1. FAM49B expression in PDAC and its correlation with LN invasion (a) Representative sections of tumors showing positive and
negative immunostaining for FAM49B. The scale bars represent a 100-μm inset, × 600 magnification. (b) LN metastasis percentage in PDAC
patients with positive and negative FAM49B expression. (c) Comparison of the proportions of a total of 89 patients with positive (n= 23) and
negative (n= 65) FAM49B expression and positive lymph nodes. The results were analyzed with the Mann–Whitney U-test. (d) Representative
sections of different grading derived from the PDAC GEM mouse models (LSL-KrasG12D/+, Pdx-1-Cre (KC); LSL- KrasG12D/+, LSL-Tp53R172H/+
and Pdx-1-Cre (KPC)) at different ages 3, 6, 9 and 12 months (n= 8/age). The scale bar represents 100-μm.
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Figure 2. FAM49B expression in PDAC is downregulated by the surrounding microenvironment (a) Differential expression of FAM49B in
normal ducts (NDs), PDAC biopsies, PDAC xenotransplants and the PDAC cell line Paca44, according to the microarray data. The data are
shown as base-two logarithm ratios of the intensity values to the median intensity values of normal pancreas tissue. (b) The relative
expression levels of FAM49B mRNA in HPDE cells and different PDAC cell lines were evaluated by qPCR. β-actin was used as a reference gene.
(c) FAM49B protein expression in different PDAC cell line and HPDE cell line was analyzed by western blotting. Actin was used as a loading
control. (d) Experimental scheme showing the syngeneic orthotopic cell line-derived xenograft model. (e) FAM49B expression in the K8484
murine PDAC cell line was analyzed ex vivo (day 0) and after 7 and 14 days of in vitro culture and 3D culture by qPCR. Actin was used as a
reference gene. (f) FAM49B expression in CFPAC1 and T3M4 PDAC cells and normal HPDE cells cultured in 3D Matrigel embedded for 14 days
or in in vitro 2D monolayer cultures, expression levels was analyzed by qPCR. Actin was used as a reference gene. (g) FAM49B expression in
CFPAC1, T3M4 PDAC cells cultured in 3D Matrigel for 14 days in comparison with the and Normal HPDE cell. All experiments were performed
at least three times, and the data are represented as the mean± s.e.m. (*Po0.05, **Po0.001, and ***Po0.0001 are values significantly
different from control or untreated samples).
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PANC1), as well as in the primary human pancreatic duct epithelial
(HPDE) non-tumor cell line (Figure 2b), compared to normal
human pancreatic duct tissues. Western blot analysis confirmed
that FAM49B expression levels were higher in all the PDAC cell
lines than in the HPDE cell line (Figure 2c) and that FAM49B
expression was not detectable in the normal pancreatic duct
(Supplementary Figure 1B).
Our finding that FAM49B expression levels were higher in PDAC
cell lines than in tumor tissues suggests that FAM49B expression is
downregulated by the tumor environment. To confirm this
hypothesis, we kinetically evaluated FAM49B ex vivo expression
in orthotopically injected PDAC cells. KPC-derived K8484 murine
PDAC cells expressing FAM49B (Supplementary Figure 1C) were
orthotopically injected into syngeneic mice. After 30 days, the
tumors were excised and dissociated, and the cells were analyzed
for FAM49B expression (Figure 2d). On day 0, ex vivo mRNA
analysis showed that FAM49B transcription was almost completely
absent. However, when the K8484 cells were cultured again over
7–14 days, FAM49B expression increased significantly (Figure 2e).
The extracellular matrix (ECM) can interact with tumor cells to
influence their cellular behavior, such as migration, adhesion and
proliferation. To evaluate the regulation of FAM49B expression by
the ECM, we cultured CFPAC1 and T3M4 PDAC cell lines in a three-
dimensional (3D) culture, by embedding cells in Matrigel or
seeding cells on Matrigel coated plates, as the cell-cell and cell-
ECM interactions that characterize this environment more closely
mimic those of the natural environment found in vivo.27 After
spheroid formation (Supplementary Figure 1D), RNA and protein
Figure 3. FAM49B functions as a metastasis suppressor. (a) shCTRL (gray circles) and shFAM49B (black circles) CFPAC1 and T3M4 cell
proliferation was evaluated by MTT assay. The data are shown as the mean± s.e.m. OD at 570 nm of three independent experiments. (b) BrdU
staining (green) in shCTRL and shFAM49B CFPAC1 and T3M4 cells. Cell nuclei are stained with Hoechst (blue). The graphs in the right panel
represent the results of the quantification of BrDU-positive cells, as determined by immunofluorescence analysis of shCTRL (gray bars) and
shFAM49B (black bars) CFPAC1 and T3M4 cells. Data are shown as the mean± s.e.m. of three independent experiments. (c) Wound-healing
assays of shCTRL and shFAM49B CFPAC1 and T3M4 cells. The dotted lines indicate the wound edge at 0 h. Migration of individual cells over
16–24 h was tracked using ImageJ. The results are represented as wound closure percentage bars representing the mean values± s.d. of three
experiments. (d) Statistical analysis of the results of the Matrigel invasion assays of shCTRL and shFAM49B cells. The results are expressed as
the mean± s.e.m. of three independent experiments. (e) Lung metastasis assay of CFPAC1 cells transfected with shCTRL or shFAM49B.
Representative hematoxylin–eosin (H&E) images of the lung metastases are shown scale bar represents 200 μm. Tumor metastases were
quantified in the histological sections, n= 4 per group, by ImageJ. Student’s t-test was used to determine the significance of the differences
between the groups (*Po0.05, **Po0.001, ***Po0.0001, Student’s t-test).
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were isolated from the cells and analyzed for FAM49B expression.
PDAC cells cultured in 3D displayed an almost complete down-
regulation of FAM49B compared to PDAC cells cultured on a 2D
monolayer (Figure 2f) or normal HPDE cells (Figure 2g). Normal
HPDE cells did not display the same downregulation of FAM49B
when cultured in 2D and 3D conditions (Figure 2f). PDAC cells
cultured on Matrigel coated plates showed a similar trend in the
downregulation of FAM49B expression, while no changes were
observed for HPDE cells (Supplementary Figure 1E). Even the
murine PDAC cell line K8484 cultured in 3D conditions showed no
detectable levels of FAM49B transcript at both 7 and 14 days
(Figure 2e). To check possibility that downregulation of FAM49B
expression in tumor microenvironment was due to accelerated
protein degradation, we treated the PDAC cell lines CFPAC1,
T3M4, K8484 and normal HPDE cells with the proteasome inhibitor
MG132. There was no increase in the levels of FAM49B upon
proteasome inhibition both in 2D and 3D cultures (Supplementary
Figures 2A and B). These data strongly suggest that FAM49B
downregulation in tumor cells occur at transcript levels rather
than due to its protein stability.
FAM49B knockdown enhances PDAC proliferation and invasion
The low in vivo FAM49B expression levels, mentioned above,
correlate with higher PDAC LN invasion (Figure 1c). In addition,
culturing ex vivo-cultured PDAC cells in vitro strongly enhances
FAM49B expression. Those data prompted us to investigate
whether FAM49B expression limits PDAC progression and inva-
siveness. We stably knocked down FAM49B in CFPAC1, T3M4 and
HPDE cells using a short hairpin RNA (shRNA) for FAM49B
(shFAM49B) or a scrambled control (shCTRL) (Supplementary
Figures 2C and D) and evaluated their proliferation and
invasiveness Using MTT and BrdU assays, we observed that both
FAM49B-silenced PDAC cell lines proliferated significantly more
than shCTRL cells (Figures 3a and b). Wound healing and Matrigel
invasion assays revealed that FAM49B-silenced cells displayed
enhanced migration compared to control cells (Figures 3c and d).
Notably, FAM49B-silenced HPDE cells did not display increased
proliferation or migration (Supplementary Figures 3A and B).
Finally, to investigate the effects of FAM49B silencing in vivo, we
injected shFAM49B or shCTRL CFAPC1 cells into the tail veins of
immune compromised mice. The FAM49B-silenced cells spread to
the lungs of these mice, where they grew to a much greater
extent than the shCTRL cells (Figure 3e).
FAM49B silencing alters mitochondrial dynamics
The intracellular distribution of FAM49B was also investigated.
FAM49B-GFP fusion protein were overexpressed in HEK293 cells
and subjected to fluorescence protease protection assay, which
utilizes digitonin and trypsin digestion. Both treatments
eliminated the majority of the cytoplasmic proteins in the
Figure 4. Localization of FAM49B in the mitochondria. (a) Cells co-stained with Mitotracker (red) and anti-FAM49B antibody (green) was
detected by immunofluorescence. Tissue sections were analyzed with a laser scanning confocal microscope (Zeiss LSM5 Pascal, Jena,
Germany) using its multichannel acquisition mode to avoid fluorescence cross talk. Images were acquired with a × 100 oil-immersion
objective, scale bar 10 μm. The pixels indicating co-localization are shown in yellow. (b) FAM49B expression in the cytosolic (Cyto) and
mitochondria-enriched (Mito) fractions of HPDE, CFPAC1 and T3M4 cells was measured by western blot analysis. The mitochondrial marker
ATP5A was used as a control of the quality of the mitochondrial fractions. GAPDH served as a cytosolic marker.
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above-mentioned cell line, but the cells overexpressing FAM49B-
GFP partially retained the fluorescence signal, suggesting that in
addition to localizing in the cytoplasm, FAM49B also localizes in
organelles (Supplementary Figure 4A), particularly in mitochon-
dria, as demonstrated by electron microscopy (Supplementary
Figure 4B). Furthermore, confocal analysis showed that in CFPAC1
and T3M4 cells, as well as in HPDE cells, FAM49B (green) co-
localized with the MitoTracker dye (red), a finding that confirmed
its mitochondrial localization (Figure 4a). Of note, HPDE cells
showed greater cytoplasmic FAM49B expression than PDAC cells.
Western blot analysis of FAM49B expression confirmed its
predominant mitochondrial localization (Figure 4b).
We employed MitoTracker RED staining to assess whether
FAM49B silencing affected mitochondrial morphology. We found
that shCTRL cells exhibited many more interconnected, elongated
and tubular mitochondria than their counterparts, while
shFAM49B cells, including HPDE cells, displayed more punctuated
mitochondria than other cells (Figures 5a and b).
Mitochondrial dynamics are driven by fission and fusion
machinery. DRP1 phosphorylation, a hallmark of fission,28 was
induced in shFAM49B CFPAC1 cells and was increased in
shFAM49B T3M4 and HPDE cells (Figure 5c), whereas fusion-
related protein, MFN1 and MFN2 expression,29 was not modified
by FAM49B silencing (Figure 5c). These data suggest that FAM49B
maintains mitochondrial health status, as its absence favors fission
in normal and PDAC cells. These findings were also confirmed by
our observation of a decrease in mitochondrial membrane
potential (Δψm), which is considered a consequence of fission
(Supplementary Figure 4C), but FAM49B silencing is not associated
to the induction of apoptosis as no changes were observed in the
cytochrome c release or caspase 9 and 3 activation
(Supplementary Figures 4D and E). In addition, FAM49B
re-expression in silenced cells restored the elongated and
interconnected mitochondrial morphology (Supplementary
Figure 4F) suggesting that FAM49B expression regulates the
mitochondrial dynamics.
Figure 5. FAM49B regulates mitochondrial dynamics. (a) MitoTracker staining was used to analyze mitochondrial morphology in CFPAC1,
T3M4 and HPDE cells. The cells were analyzed with a laser-scanning microscope (Zeiss LSM5 Pascal). (b) Quantitation of the mitochondrial
morphologies observed in the cells described in a, n450 cells, was blindly performed by three people in three independent experiments. The
bars represent the mean percentages of the mixed (black bars), tubular (gray bars) or fragmented (red bars) mitochondrial phenotypes from
one representative experiment. (c) CFPAC1, T3M4 and HPDE cell lysates were analyzed for mitochondrial dynamics regulator expression by
western blotting with anti-FAM49B, anti-DRP1, anti-MFN1, and anti-MFN2 Abs. Actin was used as a loading control.
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FAM49B regulates oxidative stress
As FAM49B affects mitochondrial dynamics, and mitochondria are
key regulators of redox balance,30 we investigated whether
FAM49B silencing was accompanied by an increase in intracellular
ROS levels and antioxidant pathway activation. Compared to
shCTRL cells, FAM49B-silenced PDAC cells displayed much higher
levels of intracellular ROS, as well as elevated superoxide
dismutase (SOD) activity levels in their mitochondria (Figure 6a),
but not in their cytosol (data not shown). A similar trend was also
observed in HPDE cells, wherein ROS levels and SOD activity levels
were lower than in PDAC cells (Figure 6a). Glutathione (GSH)
expression levels decreased in shFAM49B cells concurrently with
the above increases in ROS levels (Figure 6b). No significant
changes were observed in NADPH oxidase activity (Figure 6c),
which indicated this enzyme is not the source of the increased
ROS levels that were detected in shFAM49B cells. As efficient
oxidative phosphorylation is associated with increased mitochon-
drial ROS production,31 we investigated electron transport chain
Figure 6. FAM49B expression alters mitochondrial function and cell redox states. (a) ROS levels (upper panels) and mitochondrial SOD activity
levels (lower panels) were evaluated in shCTRL and shFAM49B CFPAC1, T3M4 and HPDE cells. (b, c) GSH and NADPH oxidase activity levels in
shCTRL and shFAM49B CFPAC1, T3M4 and HPDE cells. (d) Analysis of mitochondrial respiratory chain complex I-IV activity levels in shCTRL and
shFAM49B CFPAC1 and T3M4 cells, expressed as nmol NAD+/min/mg mitochondrial protein for complex I, nmol Cyt c reduced/min/mg
mitochondrial protein for complexes II–III and nmol Cyt c oxidized/min/mg mitochondrial protein for complex IV. (e) shCTRL and shFAM49B
CFPAC1, T3M4 and HPDE cell oxygen consumption rates (OCRs). Antimycin was used as a positive control for PCR inhibition. (f) Relative ATP
levels in shCTRL and shFAM49B CFPAC1, T3M4 and HPDE cells. All the graphs illustrate the mean results of three independent
experiments± s.e.m. *Po0.05, **Po0.01*** and Po0.001 values indicate significant differences from shCTRL.
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(ETC) complex activity. shFAM49B cells displayed aberrant
complex III activity (Figure 6d). Consistent with the above findings,
the extent of this phenomenon was greater in PDAC cells than in
HPDE cells. Mitochondrial oxygen consumption and ATP genera-
tion were significantly decreased in FAM49B-silenced PDAC cells,
but not in FAM49B-silenced HPDE cells (Figures 6e and f),
suggesting that silencing FAM49B in PDAC cells uncouples
electron transport and ATP synthesis. The pentose phosphate
pathway (PPP), which is activated in response to intracellular ROS,
fuels lipid and nucleotide biosynthesis and sustains antioxidant
FAM49B regulates mitochondria dynamics and tumor progression
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responses to support cell survival and proliferation.32 PPP activity
levels were increased in FAM49B-silenced PDAC cells but not in
FAM49B-silenced HPDE cells (Figure 7a).
ROS act as secondary messengers that favor tumor proliferation
and invasion through ERK and AKT signaling.14,33–36 Western blot
analysis revealed the presence of increased ERK1/2 and AKT
phosphorylation in shFAM49B PDAC cells (Figure 7b), but not in
shFAM49B HPDE cells (Figure 7b), suggesting that the absence of
FAM49B significantly upregulated the pro-tumoral functions of
ROS in PDAC cells, but not in HPDE cells.
FAM49B ablation cooperates with KRAS to increase PDAC
invasiveness
As activated KRAS is present in490% of PDACs,37 to determine if
FAM49B inactivation synergizes with KRAS oncogene activation,
FAM49B was silenced the HPDE cell line expressing KRASG12V
(KRAS+shFAM49B).
In constitutive KRAS activated HPDE, FAM49B inactivation was
able to induce an increased cell proliferation, cell motility,
invasiveness, and EMT marker expression (Figures 7c–g). These
KRAS-mutated shFAM49B HPDE cells also displayed a decreased
expression of key intracellular junction components, namely, the
epithelial marker E-cadherin, and an increased expression of the
mesenchymal marker Vimentin (Figure 7g). By contrast, no
changes were observed in EMT marker expression with FAM49B-
silenced or not parental HPDE (Supplementary Figure 3C).
In addition, the mesenchymal-associated transcriptional factor
SNAIL was mostly localized into the nuclei of these cells compared
to KRAS-mutated shCTRL HPDE cells, which in general displayed a
more epithelial phenotype (Figures 7f and g). These findings
indicate that FAM49B inactivation in the presence of abnormal
KRAS activity promotes tumor progression.
DISCUSSION
This study showed for the first time that the FAM49B protein is
involved in mitochondrial fission/fusion regulation and acts as a
metastasis suppressor in PDAC. Notably, FAM49B expression was
downregulated by the PDAC tumor microenvironment, as
demonstrated by the results of our ex vivo analysis of its
transcription in tumor cells injected into mice. FAM49B expression
was significantly decreased in cells analyzed immediately after
excision and then sharply increased as early as 7 days after culture
initiation. Tumor cells exhibit different morphological character-
istics when cultured in 3D as opposed to a 2D monolayer, as 3D
culture is known to preserve cell proliferation rates, gene
expression profiles and drug sensitivities.38,39 Downregulation of
FAM49B expression in PDAC cells cultured in a 3D Matrigel
environment provided evidence indicating the ECM interacts with
PDAC cells, a critical interaction that subsequently regulates
FAM49B expression. Therefore, the dynamic and reciprocal
interactions between tumor and stromal cells, as well as between
tumor cells and the ECM, are crucial for the downregulation of
FAM49B expression, which is associated with PDAC metastasis.
Most of the patients who had lower LN invasion percentages were
positive for FAM49B, while the patients with higher LN invasion
percentages were negative for FAM49B.
We show that the loss of FAM49B expression occurring in
human PDAC correlates with the invasion of the PDAC. We used
two mouse models of spontaneous and autochthonous PDAC,
namely KC and KPC that fully recapitulate the human disease,
Both mouse models shows similar progressive loss of FAM49B
expression during pancreatic lesion progression: FAM49B expres-
sion was at lower levels in normal acinar cells consistent with
results in human tissues, and increased in acinar-to-ductal
metaplasia (ADM) and early PanIN. The cells undergoes metabolic
changes, stress and plasticity during the ADM40 as later
diminished FAM49B expression strongly correlated with increasing
severity of later PanIN lesions and FAM49B was not detected in
the tumor samples.
The tumor microenvironment is known to affect the regulation
of genes, and the expression other tumor suppressor genes, such
as BRAC1 and PTEN, is downregulated in the tumor
environment.41,42 Here, we showed that FAM49B plays a
suppressive role in PDAC, as shFAM49B PDAC cells displayed
higher proliferation and invasive ability than their counterparts,
both in vitro and in vivo, confirming our initial hypothesis.
A unique feature of FAM49B is its prevalent mitochondrial
localization. This observation was confirmed by confocal micro-
scopy and western blot analysis. Interestingly, FAM49B silencing
resulted in punctuated mitochondria, a finding reflective of an
increase in fission, in conjunction with higher DRP1 phosphoryla-
tion, which is considered the hallmark of this process. However,
MFN1/2 protein expression, which is associated with the fusion
process, was not modified by FAM49B silencing, suggesting that
the absence of FAM49B has a stronger impact on fission rather
than on fusion. Mitochondrial dynamics have been shown to play
an important role in maintaining mitochondrial morphology,
stress responses, mitochondrial DNA stability, respiratory capacity
and cellular apoptosis.21,43,44 It is worth noting that FAM49B re-
expression after FAM49B silencing led to restoration of the
elongated and tubular mitochondrial morphology.
Another phenomenon induced by FAM49B silencing in non-
tumoral and neoplastic pancreatic cells is the modification of
mitochondrial ETC complex activity, particularly complex III
activity, which results in the uncoupling of this complex from
subsequent ATP synthesis. This uncoupled oxidative phosphoryla-
tion may explain the increase in mitochondrial ROS, which has
occurred in several cell models,30,45 and the parallel attempts by
cells to counter balance this ROS activity through increase in
mitochondrial SOD and PPP activity. In addition to buffering ROS,
the PPP also promotes tumor cell proliferation, prevents oxidative
cell damage and paradoxically transforms the small amounts ROS
still present from damage-inducing agents into pro-survival
signals.46
Interestingly, we demonstrated that in the context of KRAS
mutations, depleting FAM49B triggered the pro-tumoral functions
of ROS, as demonstrated by the increases in ERK1/2 or AKT
Figure 7. FAM49B downregulation enhances KRAS tumorigenesis. (a) Analysis of PPP flux in the shCTRL and shFAM49B CFPAC1, T3M4 cell
lines. Data are shown as the mean± s.e.m. of three independent experiments. (b) ERK1/2 and AKT phosphorylation in shCTRL or shFAM49B
cells was assessed by SDS–PAGE/ WB. Actin was used as a loading control. (c) shCTRL (gray circles) and shFAM49B (black circles) HPDE KRAS
cell proliferation was evaluated by MTT assay. Data are shown as the mean± s.e.m. OD at 570 nm of three independent experiments.
(d) Wound-healing assays of shCTRL and shFAM49B HPDE KRAS cells. The dotted lines indicate the wound edge at 0 h. Migration of individual
cells over 18–24 h, which was represented as wound closure percentage bars representing the mean± s.d. of three experiments, was tracked
using ImageJ. (e) Statistical analysis of the results of Matrigel invasion assays of shCTRL and shFAM49B cells. The results are expressed as the
mean± s.e.m. of three independent experiments. (f) Cells co-stained with antibodies to various markers of EMT (green) and cell nuclei stained
with Hoechst (blue), as demonstrated by immunofluorescence scale bar represent 10-μm. (g) Expression of various EMT markers, as
demonstrated by real-time PCR in shCTRL and shFAM49B HPDE KRAS cells. Actin was used as a reference gene. All graphs illustrate the mean
results of three independent experiments± s.e.m. (*Po0.05, **Po0.001, ***Po0.0001, Student’s t-test).
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phosphorylation in PDAC cells. The consequences of triggering
the pro-tumoral effects of ROS are higher cancer cell proliferation
rates and invasiveness but not in non-tumoral HPDE cells, which
has no mutation in the most commonly mutated genes as PDAC
cell lines though p53 is nonfunctional and there is loss of the Rb
gene.47 However, when KRAS is constitutively activated in non-
tumoral HPDE cells, FAM49B depletion induced an increase in
proliferation and invasion.
Regulation of ‘fusion-fission’ mitochondrial dynamics is involved
in several physiological and deregulated processes that are
classical ‘hallmarks’ of cancer,48 such as tumor metastasis.10,13
Other tumor suppressors that participate in mitochondrial
functions have been described previously. The Fus1 gene, which
modulates inflammatory responses and mitochondrial functions,
such as ROS production and mitochondrial membrane potential, is
downregulated, mutated or lost in most inflammatory thoracic
malignancies.49 A mitochondrial outer membrane channel known
as VDAC1 stabilizes HIF-1alpha by inducing ROS accumulation and
favors the growth of Ras-transformed MEF, which indicates that
the protein plays a tumor suppressive role.50 Another member of
the ‘family with sequence similarity’ is FAM96A, which has been
identified as a pro-apoptotic tumor suppressor in gastrointestinal
stromal tumors and increases mitochondria-mediated apoptosis
by binding apoptotic protease activating factor 1 (APAF1).51 In
addition, the cyclin-dependent kinase inhibitor 1B (P27) maintains
mitochondrial membrane integrity.52 These data are relevant to
our findings regarding a novel tumor suppressor gene that is
responsible for regulating mitochondrial dynamics and highlight
the role of mitochondrial integrity and metabolism in the
promotion of tumor growth and invasion.
Collectively, our findings indicate that FAM49B activity is
important for preserving mitochondrial integrity and for protect-
ing cells from oxidative stress. FAM49B is an emerging metastasis
suppressor in PDAC cells, as its downregulation leads to
mitochondria deregulation, increased cellular ROS levels and,
consequently, genomic instability and thus benefits cancer cells.
FAM49B is involved in regulating tumor metabolism and
mitochondria morphology, which has not been previously
described, and FAM49B expression is suppressed in PDAC tumors
as a selective metabolic growth advantage.
An important finding of our study is that FAM49B gene is
controlled by the tumor microenvironment, which influences
tumor metastasis by downregulating FAM49B expression. ECM
stiffness has been described as being critical for tumor progres-
sion, as it mechanically activates pro-tumorigenic signaling
pathways and also alters the metabolism of the cancer cells.53,54
ECM components negatively regulated FAM49B expression, which
we have shown to reprogram the metabolic states of cancer cells
by affecting mitochondrial dynamics, and the distribution of
mitochondria as a bioenergetics source have been described to
enhanced ECM-dependent invasion, migration and metastasis.13,55
As mitochondrial dynamic changes have an impact on cancer
metastatic potential and chemo-resistance,10,11,56 mitochondrial
fission and other vulnerable metabolic functions that are
controlled by FAM49B expression may be promising targets of
new therapeutic approaches designed to treat PDAC.
MATERIALS AND METHODS
Cell culture
PDAC cell lines CFPAC1, MIAPaCa2, BxPC3, PANC1 (obtained from ECACC),
T3M4, PT45, L3.6pl, HS766T, HPDE (kindly provided by Dr P Nisticò, Regina
Elena National Cancer Institute, Rome, Italy), normal human ductal cells
(kindly provided by Dr Lorenzo Piemonti, San Raffaele Hospital, Milan,
Italy). K8484 murine PDAC cell line (Kindly provided by Dr K Olive,
Columbia University, NY, USA). Cell lines were cultured in DMEM, RPMI and
KSF (Lonza, Basel, Switzerland) accordingly and supplemented with 10%
FBS (Lonza, Basel Switzerland) plus 50 μg/ml gentamicin (Sigma-Aldrich, St
Louis, MO, USA).
Tissue microarray analysis
For tissue microarrays (TMAs) including a retrospective series of 93
formalin-fixed paraffin-embedded (FFPE) PDACs and 20 non-neoplastic
controls were retrieved from the ARC-Net biobank at Verona University
Hospital. All specimens were from naïve-treatment patients underwent
surgery for curative intent. The materials have been collected under the
Program 1885 approved by the Integrated University Hospital Trust (AOUI)
Ethics Committee (Comitato Etico Azienda Ospedaliera Universitaria
Integrata). Four 1-mm tissue-cores per case were analyzed. Immunohisto-
chemical staining for FAM49B was performed as described.57 Two
pathologists (AS, BR) scored each tissue core in a blinded manner. Cases
were considered negative when having absent (score = 0) or weak
(score = 1) staining, and positive when having intermediate (score = 2) to
strong (score = 3) staining. Immunostaining was homogeneous among
tissue-cores from the same case.
Murine IHC analysis
Immunohistochemical staining for FAM49B was done on 4-μm-thick FFPE
Pancreatic tissues obtained from KC and KPC mouse at 3, 6, 9 and
12 months of age (n=8/age) as previously described.26 Slides were
analyzed in double blinded fashion.
In vivo studies
Orthotropic injection into the pancreases of C57B16 mice (n=6) was
performed with 1 × 105 K8484 cells. Thirty days later tumors were collected
immediately processed or cultured them in vitro after subjected to
standard enzymatic disaggregation.
For in vivo metastasis NOD-SCID IL2Rgammanull (NSG) were injected into
the tail vein (i.v.) with shFAM49B or shCTRL cells 1 × 105 (in 0.1 ml PBS),
After 28 days, mice were killed, necropsied, and examined for the presence
of tumor masses. Mice (n= 5) were used in each group. All animals were
handled in accordance with European and institutional guidelines
(Legislative Order No. 116/92, under protocol No 265/2015 PR) and
maintained at the animal facility of the Molecular Biotechnology Center,
University of Turin, Italy.
Three-dimensional culture
A total of 1.5 × 105 cells were seeded on transwell apparatuses in six-well
plates containing a 1:1 ratio of cell preparation and Matrigel (Corning GF
reduced) or were plated on plastic plates pre-coated with Matrigel. For the
embedded 3D culture the cells were incubated at 37 °C for 20–30 min to
allow the matrix to set before 1.8 ml of medium was added to the culture
plates beneath the transwell apparatus. The 3D culture was then allowed
to grow at 37 °C for ~ 7 days or 14 days, and fresh medium was added to
the culture every 2 days. Imaging was performed via inverted microscopy.
For RNA and protein extraction, the cells were isolated from the Matrigel
by dispase (Sigma-Aldrich) digestion for ~ 2 h.
Transfection
Cells were transfected using calcium phosphate precipitation method and
Lipofectamine 3000 (Life Technologies, Carlsbad, CA, USA), according to
the manufacturer’s instructions.
Knockdown experiment
MISSION shRNAs targeting human FAM49B mRNA cloned into the pLKO.1-
puro vector were purchased as glycerol stocks from Sigma-Aldrich
(SHCLNG-NM_016623). The efficiency of five shRNA with respect to
facilitating decreases in FAM49B mRNA levels was assessed by qRT-PCR in
transiently transfected cells. The two most efficient shRNAs
(TRCN0000168446 and TRCN0000168778) and control shRNA (SHC002,
Sigma-Aldrich) were chosen to generate stable cell lines using lentiviral
transduction as described.58
Protease protection assay
A GFP tag was added to the C terminus of the FAM49B delta stop codon to
facilitate protein fusion using pEGFP plasmids. HEK293T cells were
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transfected with GFP-fusion FAM49B, FPP assay was performed as
described.59
Quantitative RT–PCR
Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Hilden,
Germany), and reverse transcription was performed using 2 μg of total
RNA using an iScript cDNA Synthesis Kit (BioRad, Hercules, CA, USA),
according to the manufacturer’s instructions. Quantitative RT–PCR was
performed using SYBR Green Dye (Life Technologies) and SsoAdvanced
Universal SYBR green mix (BioRad) on a Thermal iCycler (BioRad). The PCR
reactions were performed in triplicate, and the relative amounts of cDNA
were calculated using the ΔΔCT method.
Protein lysate and western blot analysis
Protein lysate and western blot was performed as described.60
Migration assay
Wound-healing assay using Ibidi culture inserts (Thistle Scientific Ltd, UK)
according to manufacture instructions. Images were acquired along the
cell-free zone between time 0 and 24 h every 2 h. Cell migration was
assessed using ImageJ software by measuring the area covered by the
cells. Cell-free gap encroachment was determined by comparing the
results at any time point to time 0.
Invasion assay
The cell lines, with or without FAM49B silencing were evaluated with
respect to their invasion capacity using transwell Matrigel assay as
described.58
MTT assay
Cells were seeded in 96-well plates at a density of 2 × 103 cells/well and
synchronized using serum deprivation for 24 h cells were released using
complete medium and were treated with 20 μl of MTT solution (Sigma-
Aldrich; 5 mg/ml) according to manufacture instructions.
BrDu assay
Cells were seeded as MTT assay labeling for BrDu assay was performed by
adding 10 μM BrDU (BD Biosciences, Franklin Lakes, NJ, USA) according to
the manufacturer’s instructions. Hoechst was used to stain the nuclei.
Image J was used to quantify the numbers of positive cells.
Mitochondrial membrane potential analysis
Cytofluorometric analysis of the mitochondrial membrane potential was
performed on the shCNTRL and shFAM49B cell lines with 2.5 μM 5, 5′, 6, 6′-
tetrachloro-1, 1′, 3, 3′-tetraethyl- imidacar-bocyanine iodide (JC-1) (Sigma
Aldrich). Staining was performed in accordance with the manufacturer’s
instructions, and 1 μM valinomycin (Sigma Aldrich) was used as a control.
Electron microscopy
Electron microscopy was performed on HEK293 cells expressing FAM49B
GFP fusion protein. These cells were grown on Thermanox TMX coverslips
(NUNC). Embedding and staining were performed as previously
described.61
Proteasome Inhibitor analysis
MG132 (M7449 Sigma-Aldrich) used at 5 μM, at 6, 12, 24 and 48 h in 2D
culture, For the treatment of 3D culture of PDAC cells and Normal HPDE
spheroids were grown till 7 days in Matrigel and treated for 24 h with 5 μM
of MG132.
Microarray analysis
RNA was obtained from three PDAC primary tumor samples and three
adjacent normal pancreas (NP) tissue samples from the Surgery Depart-
ment of the University of Verona, as well as from eight PDAC xenografts
and one PDAC cell line (PaCa44). Microarray analysis was performed as
described.62
Mitochondria staining and analysis
The mitochondrial structural network staining was done using MitoTracker
Red (Invitrogen) according to manufacture’s instructions. Images were
recorded with an LSM5 Pascal confocal microscope and super-resolution
microscopy. The images were analyzed as previously described.63
Immunofluorescence
Cells were fixed permeabilized using Image It Kit (Life technologies)
Followed with overnight incubation of primary antibodies, at dilution 1:500
and with an Alexa Fluor secondary antibody (Life Technologies) at a
dilution of 1:200 for 1 h. Nuclei were stained with Hoechst (Life
Technologies).
Mitochondrial fraction extraction
The mitochondrial fractions were extracted via sequential-detergent
extraction with a cell fractionation kit (Mitosciences MS861, Eugene, OR,
USA), according to the manufacturer’s instructions.
ROS, SOD, NADPH oxidase, ATP and PPP activity measurements
We evaluated ROS, SOD, NADPH, ATP and PPP activity levels with the
shCTRL or shFAM49B transfected PDAC cell lines CFPAC1, T3M4, and HPDE,
as previously described.64
Mitochondrial respiratory chain activity measurement
Complex I-III activity levels were measured using non-sonicated extracted
mitochondria, as previously reported.65
Cytochrome c release
10 μg of proteins from cytosolic and mitochondrial extracts, prepared as
reported above, were probed with an anti-cytochrome c antibody (mouse,
clone 6H2.B4; BD Biosciences).
Caspase activity
The activity of caspase 9 and 3 was measuring by incubating 20 μg cell
lysates with the respective fluorogenic substrates Ac-LEHD-7-amino-4-
methylcumarine (LEHD-AMC) or DEVD-7-amino-4-methylcumarine (DEVD-
AMC), as reported.66
Antibodies and primers
Antibodies used for this study are stated in (Supplementary Table 2).
Primers stated in (Supplementary Table 3).
Statistical analysis
All experiments were repeated at least three times. Data are expressed as
the mean± s.e.m. Statistical analysis were conducted using the two-tailed
T-test or ANOVA with GraphPad Software. P values ⩽ 0.05 were considered
statistically significant.
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Supplementary Table: 1 
 
Clinicopathological variables and FAM49B expression in the 
validation cohort  
 FAM49B 
Positive 
 
FAM49B 
Negative 
Age  (35-76) n=27 n=66 
Grade   
G1   2 
G2 18 45 
G3 9 19 
LN metastasis   
N0 6 3 
N1 17    63 
pTNM stage   
I,II   
III 27 66 
IV   
 
Supplementary Table:2 
Antibody name Catalog# Supplier 
Immunoblotting 
  FAM49B pAb  ab156128 Abcam 
FAM49B pAb  HPA009076 Sigma-Aldrich 
β-actin  A2066 Sigma-Aldrich 
DRP1 (D6C7)  8570 Cell Signaling 
phospho-DRP1 (Ser616)  3455 Cell Signaling 
MFN-1 (D6E2S)  14739 Cell Signaling 
MFN-2 (D1E9)  11925 Cell Signaling 
Mitochondria fraction western 
blot cocktail ab139416 Abcam 
ERK1/2 9102 Cell Signaling 
Akt (pan) (C67E7)  4691 Cell Signaling 
AKT/MAPK signaling pathway 
antibody cocktail  ab151279 Abcam 
Phospho-AKT Ser 473 Ab 9271L Cell Signalling 
Phospho-p44/42 MAPK (Thr 
202/204) 91015 Cell Signalling 
Cytocrome C  556432 BD pharmingen 
β-Catenin (D10A8)  8480 Cell Signaling 
   Immunohistochemistry 
  FAM49B pAb  ab156128 Abcam 
FAM49B pAb  HPA009076 Sigma-Aldrich 
   Immunofluorescence 
  Vimentin (D21H3) 5741 Cell Signaling 
E-cadherin  (24E10) 3195 Cell Signaling 
Snail (C15D3) 3879 Cell Signaling 
Cell nuclei were stained with 
Hoechst H3570 Life Technologies 
MitoTracker  Red CMXRos dye 
 
Life Technologies 
Anti BrDU 555627 BD biosciences 
Alexa Fluor 488 actin conjugate A12373 Life Technologies 
Alexa Fluor 488 anti-rabbit 
secondary antibody R37116 Life Technologies 
Alexa Flour 488 anti-mouse 
secondary antibody R37120 Life Technologies 
   Electron Microscopy 
  Anti GFP A10262 Invitrogen 
Nanogold-IgG goat anti rabbit 2003 Nanoprobes 
Supplementary Table:3 
Primers used for realtime PCR 
Name Forward Primer Reverse Primer 
FAM49B 
Human CTCAAGATGACAAATCCTGC CCGGTACATTGTTAATCCTC 
Bactin 
Human CGCCGCCAGCTCACCATG CCGGGACATTATTAATTCTC 
FAM49B 
Mouse CTCAAGATGACAAATCCTGC CATCACATTCCCGAATTAAGC 
Bactin 
Mouse CACGGGGACTTTTCGTCTC GGAACGCTGCGCTCATAG 
Ecadherin TGGACAGGGAGGATTTTGAG GGCGTTGTCATTCACATCAG 
Vimentin ACCCCTATGCCAGTGGAAA TCCCTGATCGCTTGATGC 
Snail TCTCCTGCACAAACATGAGG GCTTCGGAGTGAAGAAATGC 
ZEB GGAGATGGCAATTTGTCTCC TCTTCTGCACTTGGTTGTGC 
 
Bio RAD Prime PCR SYBR Green Assay: 
FAM49B Human (Assay ID: qHSACID0023408), FAM49B Mouse (Assay ID: 
qMmuCID0012372), Bactin Human (Assay ID: qHSACED0036269), Bactin Mouse 
(Assay ID: qMmuCED0027505). 
 
Primers used for cloning of FAM49B cDNA 
Name Forward Primer Reverse Primer 
FAM49B  
Human 
Delta SC  
AGCTCGAGATGACAAATC
CTGCCATACA 
TGAAGCTTTTGCAGCATGGAT
TTAATTT 
FAM49B  
Human 
ACGGATCCATGGGGAATCT
TCTTAAAGT 
TGCTCGAGTTATTGCAGCATG
GATTTAA 
 	
Supplementary Figure Legends: 
Supplementary Figure 1: (A) Kaplan-Meier survival curves for PDAC 
patients with negative (blue) and positive FAM49B expression (red). 
Comparison of effects of negative vs positive FAM49B expression on 
overall survival. Cox model adjusted for age (as a continuous variable) 
and tumor grade (B) FAM49B protein expression in four different normal 
duct cell lysates was analyzed by western blotting. Actin was used as a 
loading control. (C) FAM49B expression in the K8484 murine PDAC cell 
line, as determined by qPCR. Actin was used as a reference gene. (D) 
Light microscopic images of the 3D cultures of the CFPAC1 and T3M4 
and K8484 PDAC cell lines and fluorescence channels for F-actin 
(green) at 14 days of culture, Hoechst-stained nuclei are shown in blue. 
Scale bar respresent 10- µm. (E) FAM49B expression in CFPAC1 and 
T3M4 PDAC cells and normal HPDE cells cultured on plates coated 
Matrigel (3D base) or plates with no coating (2D) monolayer cultures, 
expression levels was analyzed by qPCR. Actin was used as a 
reference gene. All graphs illustrate the mean results of three 
independent experiments ±SEM (*p<0.05; **p<0.001, ***p<0.0001, 
Student’s t-test) 
 
Supplementary Figure 2: (A) FAM49B protein expression in CFPAC1, 
T3M4 PDAC cells, normal HPDE cells and Murine PDAC cell line 
K8484 cultured without (untreated UT) or with MG132 5 µM (treated for 
6h and 12 h). (B) FAM49B protein expression in CFPAC1 human PDAC 
cells, normal HPDE cells and Murine PDAC cell line K8484 cultured in 
3D culture with or without MG132 and compare with 2D cultures as 
control. Beta catenin levels were analysed as positive reponse of 
MG132 treatment. (C) qPCR analysis of relative FAM49B expression 
levels in the PDAC cell lines CFPAC1,T3M4 and HPDE cells which 
were transfected with shCNTRL, shFAM49B1 or shFAM49B2. Actin 
was used as a reference gene. The bars represent the mean values 
±SDs of three experiments. (D) Immunoblotting for FAM49B expression, 
which was normalized against actin, in the PDAC cell lines CFPAC, 
T3M4 and HPDE cells which were transfected with shCNTRL, 
shFAM49B1 or shFAM49B2. The data represent the mean values ±SDs 
of three experiments (*p<0.05; **p<0.001, ***p<0.0001, Student’s t-
test). 
Supplementary Figure 3: (A) MTT proliferation assay of shCTRL (Grey 
circle) and shFAM49B HPDE cells (Black circle). The data are shown as 
the mean ±SEM of three independent experiments (*p<0.05, t-test). (B) 
Wound-healing assays of shCNTRL and shFAM49B HPDE cells. The 
dotted lines indicate the wound edge at 0 h. Migration of individual cells 
over 18-24 h was tracked using ImageJ. The data represent the mean 
values ±SDs of three experiments (C) Expression of various EMT 
markers, as demonstrated by real-time PCR in shCTRL and shFAM49B 
in HPDE cell line. Actin was used as a reference gene. All graphs 
illustrate the mean results of three independent experiments ±SEM 
(*p<0.05; **p<0.001, ***p<0.0001, Student’s t-test) 
Supplementary Figure 4: (A) Subcellular localization of GFP-tagged 
FAM49B, as shown by fluorescence microscopy. 293T cells transfected 
with GFP- tagged FAM49B were subjected to protease protection 
assay, which confirmed the subcellular distribution patterns of FAM49B. 
(B) Electron micrograph showing FAM49B localization in the 
mitochondria of 293T cells transfected with GFP-tagged FAM49B. Scale 
bar represents 500nm. (C) Flow cytometry analysis of mitochondrial 
membrane potential in shCTRL and shFAM49B CFPAC, T3M4 and 
HPDE cells, as demonstrated by JC1 staining. (D) Western blot analysis 
of Cytochrome C on cytosolic and mitochondrial fractions of the 
shCTRL and shFAM49B CFPAC1, T3M4 and HPDE cells. (E) Caspase 
3 and Caspase 9 activity measured with flouroscence probe in shCTRL 
and shFAM49B CFPAC, T3M4 and HPDE cells. (F) MitoTracker 
staining was used for analysis of mitochondrial morphology in the HPDE 
cell lines silenced for FAM49B with a control vector or His FAM49B 
vector. Tissue sections were analyzed with a laser-scanning 
microscope (Zeiss LSM5 Pascal). The data represent the mean values 
±SDs of three experiments (*p<0.05; **p<0.001, ***p<0.0001, Student’s 
t-test).  	
